MPLA, a toll-like receptor 4 (TLR4) agonist with a favorable safety profile [6], is already licensed as adjuvant with immunomodulatory characteristics for vaccines (Fendrix®, hepatitis B [7]); Cervarix®, human papilloma virus [8]). The gene discussed is TLR4; the disease is hepatitis A virus infection.